Atea Pharmaceuticals, Inc. Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Boston MA United States (2014)

Organization Overview

First Clinical Trial
2017
NCT03219957
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Atea Pharmaceuticals | Atea Pharmaceuticals, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Infections (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 24
  • # of Trial APIs: 10